Comparative study of QOL of patients on Pemetrexed versus Erlotinib in Maintenance therapy for Advanced NSCLC (Other than Squamous Cell Carcinoma)

Trial Profile

Comparative study of QOL of patients on Pemetrexed versus Erlotinib in Maintenance therapy for Advanced NSCLC (Other than Squamous Cell Carcinoma)

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Jun 2018

At a glance

  • Drugs Erlotinib (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 26 Jun 2018 Status changed from recruiting to completed.
    • 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Mar 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top